Background {#Sec1}
==========

Autism spectrum disorders (ASDs) are a group of genetically and phenotypically heterogeneous neurodevelopmental disorders unified by impairment in social interaction and communication and the presence of repetitive, stereotypic behaviors \[[@CR1]\]. These behaviors present within the first 2 years of life and affect 1--2% of children worldwide \[[@CR2]\]. Although prevalent, genetic and phenotypic complexity has limited the field's understanding and treatment of ASDs. Hundreds of genetic variants acquired through multiple inheritance patterns and forms of genetic mutation have been associated with ASDs, and expression and severity of the core symptoms are heterogeneous. There is also a diversity of neuropsychiatric and somatic conditions comorbid with ASDs, such as intellectual disability, epilepsy, attention-deficit hyperactivity disorder (ADHD), language disorder, gastrointestinal symptoms, heart defects, and feeding problems \[[@CR3]\]. Consequently, ASDs are increasingly understood to result from a variety of genetic variants that converge upon common biological pathways to impair brain development and produce a core set of diagnostic behavioral impairments. Stratification of ASD variants into subtypes defined by genetic etiology or affected biological pathway is the key to understanding the altered courses of neurodevelopment that occur in ASDs and for identifying targets of pharmacological therapy \[[@CR4], [@CR5]\].

Longitudinal study of early brain development in single gene disorders with high ASD penetrance is useful for linking known genetic and biological etiologies with abnormal neurodevelopment associated with ASD. Tuberous sclerosis complex (TSC) is one such disorder \[[@CR4], [@CR6]\]. TSC is caused by pathogenic variants in the *TSC1* or *TSC2* genes that encode suppressors of mechanistic target of rapamycin complex 1 (mTORC1). MTORC1 is a protein complex that regulates metabolic processes essential to cell growth. Failure of TSC1 and TSC2 to suppress mTORC1 results in mTORC1 hyperactivation, and subsequent growth of benign hamartomas in multiple organ systems, including the lungs, kidney, eyes, skin, heart, and brain \[[@CR7]\]. In the brain, TSC neuropathology is characterized by altered cellular morphology, aberrant neuronal migration and proliferation, hypomyelination, gliosis, and disruption of laminar architecture \[[@CR8]\]. These abnormalities are most concentrated in benign hamartomas, known as cortical tubers, that are distributed along the cortical-white matter interface and visible on MRI. Diffuse pathology, remote from tubers, exists as well \[[@CR9], [@CR10]\] and is detectable with diffusion tensor MRI \[[@CR11]--[@CR13]\]. Neurological impairments including ASD, epilepsy, intellectual disability, and ADHD are often associated with TSC, with variable severity \[[@CR14]\].

TSC is amenable to prospective study of ASD neurodevelopment from birth because 40--50% of TSC patients develop an ASD \[[@CR5], [@CR15]\], TSC is typically diagnosed in utero or within the first year of life, prior to the emergence of ASD symptoms, and the genetic and biological underpinnings of TSC are well understood \[[@CR16]\]. Further, TSC neuropathology is stochastically distributed throughout the brain, disrupting multiple brain circuits, and therefore provides an MRI-detectable pathological substrate for the "developmental disconnection" model of ASD. In this model, patients with ASD fail to develop appropriate connectivity between higher order cortical regions, resulting in global underconnectivity \[[@CR17]\]. This model is appealing because it suggests a systems level, global deficit that could arise from aberration of a variety of neural mechanisms and genetic variants and thus is consistent with the genetic and phenotypic heterogeneity of ASDs \[[@CR18]\]. MRI of children, adolescents, and adults with ASD has played a key role in the formulation of this model. Recurrent diffusion-weighted MRI findings of reduced microstructural integrity of long-range white matter fiber bundles as well as repeated reports of functional hypoconnectivity suggest underconnectivity from childhood onward in ASD \[[@CR19], [@CR20]\]. In TSC, children and adolescents with ASD exhibit reduced microstructural integrity of the corpus callosum, a mediator of interhemispheric connectivity across a wide array of functionally distinct brain regions \[[@CR12], [@CR21]\], and the arcuate fasciculus, a white matter pathway key to social communication \[[@CR22]\], compared to those without ASD. Further study of other white matter structures in TSC and ASD is needed.

A caveat to the MRI ASD literature is that many of the studies report on children and adolescents and therefore describe the brain many years after the onset of the core behavioral features of ASD. These studies fail to describe the course of abnormal brain development that precedes and co-occurs with the onset of ASD symptoms. Prospective, longitudinal studies of neurodevelopment from birth through 3 years of age, or the period when ASD behaviors emerge, are needed to understand the series of early neurodevelopmental events that result in underconnectivity in childhood and beyond. Identification of brain regions that are first abnormal may improve our understanding of the biological mechanisms at play, provide pharmacological targets, improve diagnostic capability, and perhaps uncover a causal series of events that lead to underconnectivity and ASD behaviors.

Our purpose was to evaluate the relationship between white matter development over the first 2 years of life and ASD outcome at 24 months of age in TSC. We recruited TSC infants within their first year of life and imaged them with diffusion tensor imaging (DTI) at time of recruitment, 12 months of age, and at 24 months of age. At 24 months, subjects were diagnosed with or without ASD. We hypothesize that infants who go on to develop ASD exhibit global underconnectivity, or poor microstructural integrity of white matter, over the first 2 years of life compared to those who do not develop ASD.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This research was conducted under a prospective, ongoing, multisite TSC Autism Center for Excellence Research Network (TACERN) study investigating the developmental precursors of ASD in TSC via longitudinal clinical MRI, EEG, cognitive, and behavioral assessment. Infants were recruited and longitudinally evaluated at one of five TACERN sites, each with a TSC specialty clinic: Boston Children's Hospital (BCH), Cincinnati Children's Hospital Medical Center (CCHMC), University of Alabama at Birmingham (UAB), University of California Los Angeles (UCLA), and McGovern Medical School at University of Texas Health Science Center at Houston (UTH). All study procedures were approved by the Institutional Review Board at each site, and written informed consent was obtained.

Infants were enrolled between 3 and 12 months of age following diagnosis with TSC \[[@CR16]\]. Diagnosis was based on genetic or clinical diagnostic criteria for TSC, including physical exam, neuroimaging, or echocardiogram. Exclusion criteria included history of gestational age \< 36 weeks, exposure to mTOR inhibitor such as rapamycin (sirolimus) or everolimus, exposure to an investigational drug within 30 days of study enrollment, subependymal giant cell astrocytoma requiring medical or surgical treatment, neurosurgery, and contraindications for MRI.

Brain MRI was acquired at baseline, or time of enrollment, and at 12, 24, and 36 months of age, modified as required by clinical care demands. Because infants were enrolled between 3 and 12 months of age, age at baseline MRI varies across the cohort (Fig. [1](#Fig1){ref-type="fig"}). To allow a minimum 6--9 months between MRI scans, subjects with baseline MRI between 6 and 9 months of age were permitted to perform the 12-month MRI anytime between 12 and 15 months of age. If infants were enrolled between 10 and 12 months of age, the baseline MRI was foregone, and the first study MRI occurred at 12 months of age, followed by 24- and 36-month MRI scans. All MRI scans were sent to the Computational Radiology Laboratory at BCH for quality control and image processing.

Infants underwent developmental and clinical evaluations at 3, 6, 9, 12, 18, 24, and 36 months of age. The developmental evaluation consisted of standardized neuropsychological evaluation with adaptive and developmental measures by research-reliable personnel. The clinical evaluation entailed collection of baseline demographic information, baseline and interval medical history, family history, prior and concomitant medications, genetic data, clinical exam findings, and past and current seizure history. All developmental and clinical data were sent to the centralized TACERN Data Coordinating Center at UAB. A yearly calibration meeting was held to ensure developmental assessment reliability across all sites for the entire study period. Fig. 1Depiction of the MRI sample. Each point represents an MRI scan. A line connecting multiple points represents repeated MRI scans for a single patient

MRI acquisition {#Sec4}
---------------

Patient brain MRI scans were acquired at 3T on seven scanners and five scanner models, including one General Electric (GE) Signa HDxt, one Philips Achieva, three Philips Ingenia, one Siemens Skyra, and two Siemens TrioTim with 32, 12, and 8 channel head coils. Subjects were imaged under the TACERN consensus research imaging protocol that includes high resolution, routine clinical imaging sequences used for annual surveillance imaging of TSC patients. The protocol includes a 1-mm^3^ sagittal T1-weighted (T1w) MPRAGE, 0.4-mm^2^ in-plane resolution × 2-mm slice thickness axial T2-weighted (T2w) TSE, 30 high angular resolution *b* = 1000 s/mm^2^ diffusion-weighted (DW) images, and 6 *b* = 0 s/mm^2^ DW 2 mm^3^ resolution images, one with reversed phase-encoding direction for distortion compensation, covering the entire brain. Imaging protocols were harmonized to the extent permitted by each platform. Detailed acquisition parameters used on each scanner and cross-scanner reliability are detailed in a previous publication (Prohl 2019, under review) and in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Patients were imaged under sedation or in natural sleep as clinically indicated.

Quality assurance {#Sec5}
-----------------

MRI data were evaluated at the TACERN MRI Processing Center at the Computational Radiology Lab at BCH. MRI metadata were reviewed for protocol compliance. All image volumes were reviewed slice by slice by an expert rater for extent of brain coverage and artifacts resulting from a variety of sources, including but not limited to table vibration, magnetic susceptibility, subject motion, flow, radiofrequency leak, and venetian blind artifact \[[@CR23], [@CR24]\]. Diffusion-weighted volumes with artifact were removed prior to analysis.

MRI processing {#Sec6}
--------------

All MRI processing and analyses were completed using the Computational Radiology Kit ([http://crl.med.harvard.edu](http://crl.med.harvard.edu/)) via a fully automated processing pipeline. In the native space of each scan, the T2w image was aligned and resampled to the 1 mm^3^ T1w image using rigid registration with mutual information metric. The intracranial cavity (ICC) was then segmented using a previously validated multispectral ICC segmentation method \[[@CR25]\], and the ICC was masked from the T1w and T2w images.

The DW images were corrected for magnetic susceptibility distortion using the pair of *b* = 0 images with opposite phase-encoding direction and FSL topup \[[@CR26]\]. Inter-volume motion correction was then performed by affine registration of each DW image to the average *b* = 0 s/mm^2^ image. The DW images were aligned and up-sampled to the 1 mm^3^ T1w scan using affine registration and sinc interpolation, and the brain extracted on DWI using the previously computed ICC segmentation \[[@CR27]\]. A single tensor diffusion model was estimated using robust least squares in each brain voxel from which fractional anisotropy (FA = 3Var(*λ*)/(*λ*^2^~1~ + *λ*^2^~2~ + *λ*^2^~3~)^1/2^) and mean diffusivity (MD = (*λ*~1~ + *λ*~2~ + *λ*~3~)/3) were computed \[[@CR28]\].

Automatic ROI delineation {#Sec7}
-------------------------

Next, a fully automatic, multi-template approach was used to define 17 white matter regions of interest (ROIs) in the native space of each subject DTI scan using a previously validated method \[[@CR29]\]. A template library was constructed from whole brain DTI of 20 healthy children, with each scan in its native space. The DTI were computed from 30 high angular resolution *b* = 1000 s/mm^2^ and 5 *b* = 0 s/mm^2^ TACERN protocol DW images acquired on a 3T Siemens Skyra scanner at BCH.

For each template, scalar FA and color maps of the principal diffusion directions were computed from the DTI. ROIs were hand drawn by an expert rater on the color map within white matter fiber bundles following previously defined and validated labeling schemes for tractography \[[@CR30]--[@CR32]\]. To delineate the same white matter ROIs in the native space of each subject scan, the following procedure was performed for every template: the template scalar FA map was aligned to the target subject scalar FA map using affine registration with mutual information metric. The affine registration field was used to initialize a non-linear, dense registration of the template DTI to the subject DTI, for a total of 20 non-linear dense registrations per scan, and 3740 non-linear dense registrations in the sample of 187 MRI scans. The affine and dense deformation fields were then used to resample the template white matter ROIs to the subject native DTI space using nearest neighbor interpolation. Now with 20 sets of white matter ROIs (one for each template) aligned to the native space of the subject scan, a final, consensus set of white matter ROIs was computed using the STAPLE algorithm \[[@CR33]\]. Lastly, mean FA and MD were computed in each ROI.

White matter ROIs {#Sec8}
-----------------

The ROIs analyzed in this analysis were defined using previously validated labeling schemes for tractography and include left and right posterior limb of the internal capsule, anterior limb of the internal capsule, cingulum body, inferior extreme capsule, and corpus callosum following \[[@CR30]\]. Briefly, the ALIC and PLIC ROIs were drawn in the axial plane. The inferior limit of the ROIs was defined on the first axial slice superior to the anterior commissure, and the superior limit was defined on the axial slice where the lenticular nucleus separates the internal and external capsules. The cingulum was defined in the axial plane with a single ROI in each hemisphere covering the cingulum body. The inferior anterior limit of the ROI was defined in plane with the inferior genu of the corpus callosum, and the inferior poster limit was defined in plane with the inferior splenium of the corpus callosum. The superior ROI limit was defined on the most superior green fibers of the cingulum. The inferior extreme capsule ROIs were defined in the coronal plane. The posterior limit of the ROI was defined by the first slice anterior to the apex of UF curvature and covered ten slices of green-blue, fronto-temporal fibers anterior to the posterior limit. This approach deviates from the approach taken in Catani 2008, but produced accurate and reliable tractography and therefore was implemented. The corpus callosum ROI was drawn in the sagittal plane and covered the body of the corpus callosum with 10 mid sagittal slices (5 slices in each hemisphere) \[[@CR30]\]. The sagittal stratum was defined in the coronal plane following the labeling technique for tractography of the optic radiation, presented in \[[@CR32]\]. Briefly, the anterior limit of the ROI was defined on the coronal slice immediately posterior to the splenium of the corpus callous and the extended posteriorly for a total of 5 coronal slices. All green fibers were labeled with the purpose of capturing the optic radiations \[[@CR32]\]. The arcuate fasciculus ROIs were placed following the labeling scheme presented in \[[@CR22]\]. Three ROIs were placed along the arcuate fasciculi in each hemisphere; in the white matter (1) projecting from the inferior parietal lobule to the inferior frontal gyrus, (2) underlying the inferior parietal lobule, and (3) underlying the posterior superior temporal gyrus. From here on, we refer to these ROIs as left and right arcuate fasciculus waypoint to Broca's, Geschwind's Territory, and Wernicke's area, respectively (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2White matter regions of interest (ROI) superimposed on a color map of the principal diffusion directions. Red color map voxels indicate left-right diffusion, green color map voxels indicate anterior-posterior diffusion, blue color map voxels indicate inferior-superior diffusion, and other colors indicate intermediate diffusion directions. Four axial slices from a single scan depict 2D slices of 3D white matter ROI, outlined in unique colors: light blue = cingulum, green = corpus callosum, white = arcuate fasciculus waypoint to Broca's; royal blue = arcuate fasciculus Geschwind's territory, red = anterior limb of the internal capsule, orange = posterior limb of the internal capsule, yellow = arcuate fasciculus Wernicke's area, pink = sagittal stratum, and purple = uncinate fasciculus

Developmental measures {#Sec9}
----------------------

The TACERN battery consists of multiple measures administered longitudinally that measure the extent of ASD symptomatology and developmental status of TSC infants \[[@CR34]\]. Here, we focus on two of these measures administered at 24 months of age. First, the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) is a semi-structured, interactive observation schedule designed to assess individuals who may have an ASD and consists of 5 modules \[[@CR35], [@CR36]\]. The specific module (toddler, 1, or 2 were applicable to our cohort) was determined by the ADOS-2 administrator at the time of the assessment. Based on the overall total sum of selected items from the social affect and restricted and repetitive behavior domains, the Toddler Module yields classifications of little-to-no concern, mild-to-moderate concern, and moderate-to-severe concern for ASD and modules 1 and 2 yield classifications of non-spectrum, autism spectrum, or autism.

Second, the Mullen Scales of Early Learning (MSEL) was also completed at 24 months of age \[[@CR37]\]. The MSEL provides an assessment of developmental functioning for children ages 0--5, with domain scores for fine and gross motor skills, visual reception, receptive and expressive language, and an overall early learning composite score. Developmental quotient (DQ) was used in lieu of the early learning composite score in order to capture the performance of low scoring subjects for whom standard scores were not available given their age and raw score. The DQ is equal to the average of fine motor, expressive language, receptive language, and visual reception developmental quotients. A DQ was computed for each domain and was equal to (domain age equivalent ÷ chronological age)× 100.

Epilepsy measures {#Sec10}
-----------------

Parents recorded seizure types, seizure frequencies, and antiepileptic medications in a seizure diary over the study period, and data were collected at all clinical visits (3, 6, 9, 12, 18, 24, and 36 months of age). Epilepsy severity at 24 months of age was quantified by summing the number of seizure types and number of antiepileptic drugs used from 12 to 24 months of age. These two severity items were selected because they are good measures of epilepsy severity in TSC \[[@CR38]\] and were available in all analyzed subjects.

Statistical analysis {#Sec11}
--------------------

Statistics were completed using R version 3.5.1 and R Studio version 1.1.456 \[[@CR39], [@CR40]\]. Linear mixed effects (LME) modeling was performed to test the hypothesis that infants who develop ASD exhibit poor white matter microstructural integrity over the first 2 years of life compared to those who do not develop ASD. LME modeling is an appropriate method because it accommodates missing data and repeated measures. Missing data were not imputed and all available measurements were included under the missing-at-random assumption.

Longitudinal trajectories of FA and MD for each white matter ROI over the first 24 months of life were modeled using the lme4 package \[[@CR41]\]. For each DTI metric (FA or MD) and in each white matter ROI, we computed a random intercept LME model in the natural logarithm of age, for a total of 34 models (17 white matter ROIs, 2 DTI metrics). Due to the rapid change in the brain microstructure in the first year of life, the natural logarithm of age at MRI scan was taken to linearize the model. Natural log of age at MRI scan was then broken into two components: (1) baseline age, or age at the subject's first MRI scan in the sample, and (2) longitudinal age, or age at MRI scan minus baseline age. Age was split into these two components in order to separate the cross-sectional effect, which captures the relationship between DTI metrics and age at first MRI scan, from the longitudinal effect, which captures rate of change of DTI metrics and age \[[@CR42]\]. In our sample, cross-sectional age (or age at first MRI scan) varied from 0.22 to 2.1 years of age, and thus, modeling the cross-sectional effect and longitudinal effect separately is appropriate \[[@CR43]\].

In addition to baseline age and longitudinal age, other fixed effects of interest included group, sex, interaction of group with baseline age, and interaction of group with longitudinal age. To create a binary group variable (TSC-ASD, TSC+ASD) from the 24 month ADOS, infants were considered TSC-ASD if classified as little-to-no-concern on the Toddler Module or as non-spectrum on modules 1 and 2. Infants were considered TSC+ASD if classified as mild-to-moderate or moderate-to-severe-concern on the Toddler Module or as autism spectrum or autism on modules 1 and 2. Subject was modeled as a random intercept to capture between subject variability.

Likelihood ratio tests were used to evaluate the significance of each term to the model. Sex was dropped as it did not reach significance. For every ROI, the final model consisted of the following: $$\documentclass[12pt]{minimal}
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where *y* = FA or MD, *β* = fixed effect coefficient*, ϑ* = random effect coefficient*, i* indexes subject, and *j* indexes scan within each subject. I. The units of age_baseline and age_longitudinal are ln(years). The error term in the above model is assumed to identically independently distributed as *εij*\~*N*(0, *σ*^2^), and the distribution of random-effects is assumed to be multivariate normal with mean 0 and variance covariance matrix Σ*ϑ*, i.e., (*ϑ*~0*i*~)\~*N*(0, *Σ*~*ϑ*~).

Sample {#Sec12}
------

Inclusion criteria for the present analysis were (1) ADOS completed at 24 months of age and (2) one or more successful MRI scans with DWI. These criteria were met by 115 of 143 infants enrolled in the study. Two hundred eighty-eight scans were available from the 115 infants who met inclusion criteria. Of the 288 scans available for analysis, 76 scans collected at the 36-month time point were excluded, 18 scans were post-neurosurgical and therefore excluded, and 6 scans were excluded due to quality of the DWI. This yielded a sample of 108 subjects (62 TSC-ASD, 55% male; 46 TSC+ASD, 52% male) with 187 MRI scans (109 TSC-ASD; 78 TSC+ASD) for analysis (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). One hundred eighty-four of 187 scans featured no evidence of hardware or patient-induced artifact, and therefore, 30 high angular resolution *b* = 1000 s/mm^2^ DW images were processed. Two of 187 scans required removal of a single gradient volume due to patient motion. One of 187 scans required removal of 10 gradient volumes due to patient motion. One hundred one (94%) of subjects were scanned in a single scanner for all study visits. Seven subjects were scanned on 2 scanners over the course of their study visits. Sedation was used as clinically indicated in 186 of 187 scans. Table 1Descriptive data of the sample by diagnostic outcome groupTSC-ASDTSC+ASD*tp*Subjects (*n*, %)62, 57%46, 43%Sex (% male)55%52%MSEL developmental quotient at 24 months ($\documentclass[12pt]{minimal}
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Results {#Sec13}
=======

Descriptive statistics {#Sec14}
----------------------

Descriptive data of the sample by diagnostic outcome group is available in Table [1](#Tab1){ref-type="table"}. Subjects with ASD exhibited a significantly lower MSEL DQ (*t* = 7.6, *p* = 1.7 × 10^−11^) and significantly higher epilepsy severity score (*t* = ^−^4.8, *p* = 6.1 × 10^−6^) at 24 months of age compared to TSC subjects without ASD (Table [1](#Tab1){ref-type="table"}). Subjects with ASD had greater severity of ASD symptoms overall as measured by the ADOS calibrated severity score, as expected (*t* = ^−^15.5, *p* \< 2.2 × 10^−16^). Descriptive data of the MRI sample by diagnostic outcome group is available in Table [2](#Tab2){ref-type="table"}. The distribution of scans across baseline, 12 months, and 24 months of age was similar between groups. In subjects with ASD, 15% of scans were acquired at baseline, 43% of scans were acquired at 12 months, and 42% of scans were acquired at 24 months. In subjects without ASD, 19% of scans were acquired at baseline, 40% of scans were acquired at 12 months, and 41% of scans were acquired at 24 months. There were no group differences in age at 12-month or 24-month MRI scan. Subjects with ASD were imaged at baseline significantly later (0.6 ± 0.2 years) than subjects without ASD (0.4 ± 0.2) (*t* = ^−^2.1, *p* = 0.04). Table 2Descriptive data of the MRI sample by diagnostic outcome groupTSC-ASDTSC+ASDScans (subjects) with ADOS163 (66)125 (49) Excluded: 36-month scans (*n*)4432 Excluded: Post-surgical scans (*n*)513 Excluded: DWI artifact scans (*n*)42Total scans (subjects) in sample109 (62)78 (46)Sedated scans (*n*, %)109, 100%77, 99%Baseline MRI (*n*, %)16, 15%15, 19%12 months MRI (*n*, %)47, 43%31, 40%24 months MRI (*n*, %)46, 42%32, 41%Age at baseline MRI ($\documentclass[12pt]{minimal}
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Longitudinal mixed effects models: trajectories of white matter development {#Sec15}
---------------------------------------------------------------------------

To test the hypothesis that white matter maturation varied as a function of diagnostic outcome group (TSC+ASD or TSC-ASD), a random intercept mixed effects model was computed for each DTI metric (FA and MD) in each white matter ROI, for a total for 34 models. For all white matter regions, FA significantly increased with baseline age and longitudinal age, and MD significantly decreased with baseline age and longitudinal age, as expected (Additional file [1](#MOESM1){ref-type="media"}: Table S2 and Table S3).

In all white matter regions, the main effect of group reduced FA, indicating that FA trajectories were lower in TSC+ASD compared to TSC-ASD. This effect of group on FA reached statistical significance in 9 of 17 white matter regions analyzed: left arcuate fasciculus waypoint to Broca's (*χ*^2^ (1) = 6.07, *p* = 0.01), left arcuate fasciculus Geschwind's territory (*χ*^2^ (1) = 5.62, *p* = 0.02), left arcuate fasciculus Wernicke's area (*χ*^2^ (1) = 12.41, *p* \< 0.001)), right arcuate fasciculus waypoint to Broca's area (*χ*^2^ (1) = 11.42, (*p* \< 0.001), left anterior limb internal capsule (*χ*^2^ (1) = 4.42, *p* = 0.04), right anterior limb internal capsule (*χ*^2^ (1) = 9.22, *p* = 0.002), left cingulum (*χ*^2^ (1) = 4.48, *p* = 0.03), corpus callosum (*χ*^2^ (1) = 11.66, *p* \< 0.001), and right sagittal stratum (*χ*^2^ (1) = 6.55, *p* = 0.01) (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Table 3Longitudinal mixed effects model results for effect of group (TSC+ASD and TSC-ASD) and group interactions with age on fractional anisotropy of white matter regions. Likelihood ratio tests were used to attain *p* values. Italicized *p* values indicate *p* \< 0.05White matter region of interestGroupGroup × baseline ageGroup × longitudinal ageEst*χ*^2^*p*Est*χ*^2^*p*Est*χ*^2^*p*LeftArcuate: waypoint to Broca's− 0.0186.07*0.01*− 0.0171.400.240.0061.010.32Arcuate: Geschwind's territory− 0.0165.62*0.02*0.0040.080.780.0040.960.33Arcuate: Wernicke's area− 0.02312.41*\<0.001*− 0.0060.240.620.0051.100.30Anterior limb internal capsule− 0.0154.42*0.04*0.010.470.490.0020.210.65Cingulum− 0.0114.48*0.03*− 0.0090.660.420.0020.270.61Inferior extreme capsule− 0.0061.180.28− 0.0020.020.880.0010.030.86Posterior limb internal capsule− 0.0091.460.23− 0.0050.140.71− 0.010.530.47Sagittal stratum− 0.0030.100.750.0231.450.230.0040.220.64MidlineCorpus callosum− 0.02411.66*\<0.001*− 0.0080.390.540.0071.630.20RightArcuate: waypoint to Broca's− 0.02411.42*\<0.001*0.0060.190.660.0061.560.21Arcuate: Geschwind's territory− 0.0040.420.520.0131.120.29− 0.0000.020.90Arcuate: Wernicke's area− 0.0133.970.050.0040.080.780.0020.260.61Anterior limb internal capsule− 0.0209.22*0.002*0.0010.010.940.0030.340.56Cingulum− 0.0103.940.050.0000.000.990.0073.050.08Inferior extreme capsule− 0.0020.160.690.0100.920.34− 0.0020.490.48Posterior limb internal capsule− 0.0030.310.580.0030.060.81− 0.0020.130.72Sagittal stratum− 0.0226.55*0.01*0.0231.780.180.03513.48*\<0.001*Italicized *p* values indicate *p* \< 0.05 Fig. 3Fractional anisotropy of white matter regions of interest plotted as a function of natural logarithm of age in the TSC+ASD and TSC-ASD groups. Points represent MRI scans. Dashed lines represent raw FA trajectories for each subject. Solid lines represent the mean LME model fit

The interaction of baseline age and group did not significantly affect FA in any white matter regions. The interaction of group and longitudinal age significantly decreased FA in the right sagittal stratum only, indicating that with age, FA of the right sagittal stratum diverges between TSC+ASD and TSC-ASD, with TSC+ASD exhibiting a reduced FA over time (*χ*^2^ (1) = 13.48, *p* \< 0.001) (Table [3](#Tab3){ref-type="table"}).

In contrast to FA, the main effect of group did not significantly affect MD in any white matter regions. In all bilateral arcuate ROI, bilateral sagittal stratum, and the corpus callosum, the main effect of group increased MD, indicating that MD trajectories were higher in TSC+ASD compared to TSC-ASD; however, none of these effects were statistically significant. In the bilateral anterior limb internal capsule, bilateral posterior limb internal capsule, bilateral cingulum, and bilateral inferior extreme capsule, MD trajectories were higher in TSC-ASD compared to TSC+ASD, although none of these effects were significant (Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Table 4Longitudinal mixed effects model results for effect of group (TSC+ASD and TSC-ASD) and group interactions with age on mean diffusivity of white matter regions. Likelihood ratio tests were used to attain *p* values. Italicized *p* values indicate *p* \< 0.05. Model estimates are scaled × 1000White matter region of interestGroupGroup × baseline ageGroup × longitudinal ageEstimate*χ*^2^*p*Estimate*χ*^2^*p*Estimate*χ*^2^*p*LeftArcuate: waypoint to Broca's0.0110.710.400.0230.780.38− 0.0040.110.74Arcuate: Geschwind's territory0.0293.010.080.0522.400.12− 0.0131.430.23Arcuate: Wernicke's area0.0050.110.740.0150.220.64− 0.0040.170.68Anterior limb internal capsule− 0.0090.700.400.0241.140.290.0070.710.40Cingulum− 0.0050.460.500.0252.410.120.0020.040.84Inferior extreme capsule− 0.0050.390.530.0201.670.200.0101.340.25Posterior limb internal capsule− 0.0060.320.570.0251.430.230.0040.180.67Sagittal stratum0.0040.030.850.0190.190.670.0211.640.20MidlineCorpus callosum0.0282.970.080.0492.250.13− 0.0020.020.88RightArcuate: waypoint to Broca's0.0253.820.050.0020.010.93− 0.0182.580.11Arcuate: Geschwind's territory0.0080.240.630.0120.150.700.0020.040.84Arcuate: Wernicke's area0.0060.180.680.0230.610.43− 0.0030.080.78Anterior limb internal capsule− 0.0091.070.300.0170.930.340.0060.470.49Cingulum− 0.0070.810.370.0181.300.25− 0.0040.220.64Inferior extreme capsule− 0.0060.720.390.0110.680.410.0122.220.14Posterior limb internal capsule− 0.0040.230.630.0170.980.320.0060.740.39Sagittal stratum0.0220.880.350.0450.970.32− 0.0564.17*0.04*Italicized *p* values indicate *p* \< 0.05 Fig. 4Mean diffusivity of white matter regions of interest plotted as a function of natural logarithm of age in the TSC+ASD and TSC-ASD groups. Points represent MRI scans. Dashed lines represent raw FA trajectories for each subject. Solid lines represent mean LME model fit.

The interaction of baseline age and group did not significantly affect MD in any white matter regions. The interaction of group and longitudinal age significantly decreased MD in the right sagittal stratum only, indicating that with age, MD of the right sagittal stratum diverges between TSC+ASD and TSC-ASD, with TSC+ASD exhibiting a reduced MD over time (*χ*^2^ (1) = 4.17, *p* = 0.04) (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec16}
==========

We carried out a large prospective longitudinal study of TSC subjects. We assessed white matter maturation over the first 24 months of life and compared the trajectories of white matter maturation in subjects with and without ASD. In 9 of 17 white matter regions evaluated, TSC+ASD subjects exhibited disrupted microstructural integrity of the white matter compared to TSC-ASD subjects. The regions were the arcuate fasciculi, corpus callosum, cingulum, sagittal stratum, and anterior limb of the internal capsule. These results suggest that underconnectivity across multiple white matter fiber bundles develops prior to and concurrent with the emergence of ASD behavioral features over the first 2 years of life.

We also found subjects who were later diagnosed with ASD had higher severity of epilepsy and increased intellectual disability. Therefore, some of the changes in white matter properties may be associated with the higher incidence of epilepsy or the higher incidence of intellectual disability. Indeed, previous work has found the effects of ASD, epilepsy, and IQ on white matter microstructural abnormality to be additive; the more neurological comorbidities, the more abnormal the white matter, with ASD diagnosis contributing the most to abnormal white matter microstructure \[[@CR21]\]. Given the widespread distribution of disease burden in TSC that affects multiple white matter pathways and therefore multiple brain functions, it follows that patients with greater overall neuropathological burden are at greater risk for impaired social functioning as well as impaired functioning in other domains. Larger studies with more subjects, exhibiting a full range of epilepsy severity and developmental functioning, are needed to assess the contribution of white matter maturation to each outcome.

Fronto-temporal and fronto-limbic pathways {#Sec17}
------------------------------------------

Four of the six fronto-temporal/fronto-limbic fiber bundles examined exhibited reduced FA in ASD. FA was reduced in all left arcuate regions and in the waypoint to Broca's region on the right, compared to subjects without ASD. These findings indicate that previously reported abnormality of the arcuate in children and adults with TSC+ASD \[[@CR22]\] originates early in the brain development. Reduced arcuate FA \[[@CR19]\] and reduced FA of white matter underlying the temporoparietal junction \[[@CR44]--[@CR46]\] is also reported in children and adults with nsASD compared to controls. These findings are noteworthy because the AF supports temporoparietal cortex involved in social communication. The bilateral posterior STG mediate audition and phoneme discrimination within the first 6 months of life and play a key role in detecting speech prosody \[[@CR47]\]. A 12-month-old infants later diagnosed with ASD exhibit reduced sensitivity to human voices and deficits in expressive and receptive language \[[@CR15], [@CR48], [@CR49]\] compared to low-risk controls. The posterior superior temporal sulci are also implicated in the analysis of dynamic, biologically relevant stimuli, including eye-gaze, facial expressions, and body movements \[[@CR50], [@CR51]\]. During gaze and facial processing tasks and tasks of joint attention \[[@CR52]\], the posterior STS is consistently reported to function atypically in adults and children with ASD compared to typically developing controls. Critically, acquisition of joint attention, a behavior dependent on biological motion perception, is thought to set the stage for development of complex social communication behaviors, such as language \[[@CR53]\]. Delays in joint attention within the first 18 months of life predict later language deficits at 24 months of age in ASD \[[@CR54], [@CR55]\]. Our results contribute to mounting evidence implicating abnormality of the temporoparietal junction in ASD.

The uncinate fasciculus has also been implicated in joint attention and communication. The UF connects the orbitofrontal cortex with the anterior temporal lobe and has been proposed to play a role in joint attention \[[@CR56]\], social-emotional processing \[[@CR57]\], semantic retrieval, and sound recognition \[[@CR58]\]. Infants with non-syndromic ASD exhibit reduced UF FA from 6 to 24 months and in child and adulthood \[[@CR59], [@CR60]\]. Here, we did not find atypical maturation in the inferior extreme capsule ROIs, which lie along the uncinate fasciculus, associated with ASD. This may reflect the positioning of the ROI at the outflow of the temporal stem to the frontal lobe, which includes both UF streamlines and streamlines of the inferior occipitofrontal fasciculus that lies just superior to the UF \[[@CR61]\]. Future tractography analysis of the full UF tract will better define the relationship between the UF and TSC+ASD.

FA was also reduced in the left cingulum of subjects with ASD and approached statistically significant reduction in the right cingulum (*p* = 0.05). Reduced cingulum FA has been reported in children and adults with nsASD \[[@CR60], [@CR62]\] and has not been previously studied in infants with ASD. The cingulum connects medial aspects of the cingulate cortex with medial frontal, parietal, and temporal lobes and is predominately comprised of short U fibers that interlink these regions. The cingulum is responsible for a variety of functions related to emotion, motivation, executive function, and memory \[[@CR62]\]. The cingulum is also thought to mediate and connection between the anterior and posterior hubs of the default mode network, a functionally defined network frequently identified as abnormal in ASD. From 6 to 24 months of age, atypical default mode network connectivity is associated with ASD \[[@CR63]\] and restricted to repetitive behaviors \[[@CR64]\]. Our findings in the cingulum provide a plausible neural substrate for atypically connectivity within the default mode network in ASD.

Projection pathways {#Sec18}
-------------------

Three of the six projection fiber bundles examined exhibited reduced FA in ASD. FA was reduced in the ALIC bilaterally, a finding also reported in infants and children with nsASD \[[@CR59], [@CR65], [@CR66]\]. The ALIC contains projection fibers from the thalamus, which comprise the anterior thalamic radiation, and projection fibers from the brainstem. The thalamus is a hub of sensorimotor connectivity, and atypical thalamocortical connectivity has oft been associated with ASD \[[@CR67]\]. Thus, our findings of bilateral reduced ALIC FA are in line with previous reports of ALIC underconnectivity. We did not find group differences in the posterior limb of the internal capsule.

Commissural pathways {#Sec19}
--------------------

We found reduced FA of the corpus callosum associated with TSC+ASD. This finding aligns with previous reports of reduced CC FA in children and adults with TSC+ASD \[[@CR12], [@CR21]\], children and adults with nsASD \[[@CR19]\], and infants with nsASD \[[@CR59]\]. The primary role of the CC is to mediate interhemispheric connectivity, and it is attributed functions of complex processing, working memory, and overall cognition. Corpus callosum abnormalities are the most consistently reported finding in nsASD DTI literature; however, a consistent link between atypical social functioning and corpus callosum microstructure has not been established \[[@CR19]\]. This may be due to the diversity of functions of the corpus callosum, as well as the heterogeneity of the autism symptom profile. One recent study in nsASD over the first 24 months of life found an association between microstructure of the corpus callosum genu and sensory responsiveness and restricted and repetitive behaviors, but not social functioning \[[@CR68]\]. More studies that focus on brain-behavior relationships, rather than brain-diagnostic outcome relationships, are needed to identify how variation in brain structures is associated with variation in ASD symptoms.

There are methodological points to consider about this study. First, although a wealth of functional, EEG, and DTI data suggest disrupted connectivity in ASD \[[@CR20], [@CR69]\], the validity of these findings is sometimes questioned. Head motion artifact in particular has been proposed as the cause of group difference in ASD versus typically developing control DTI studies \[[@CR70]--[@CR73]\], as FA is known to substantial decrease with DWI slice-level motion artifact \[[@CR74]\]. Here, we present longitudinal imaging data acquired in infants at high risk of ASD with a common genetic diagnosis over the period of early brain development. The data set features virtually no head motion artifact and stringent quality control for hardware-induced artifact. Thus, we consider this an ideal data set for linking atypical development of brain structures with the emergence of ASD-related behaviors.

Second, TSC+ASD was associated with reduced FA, but not elevated MD. FA reflects the degree of water anisotropy in the voxel, which is most strongly driven by the presence of axons. In contrast, MD is a measure of overall diffusivity and is highly sensitive to myelination \[[@CR75]\]. Over the first 2 years of life, rapid myelination is occurring throughout the brain at different rates in different locations in different subjects. We hypothesize that the inter-subject variability in overall water diffusion within this age range is high due to these varying rates of maturation of myelin, or other white matter microstructure, and masks our ability to detect group differences in MD. FA group differences are detectable because the primary driver of FA is the presence of the axons, myelinated or not.

Third, longitudinal imaging was not available for all subjects analyzed. Ten subjects who met inclusion criteria underwent neurosurgery for epilepsy treatment, and longitudinal, presurgical imaging was not possible. Fourth, single tensor diffusion models are limited in regions of crossing fascicles. Multi-tensor model estimation ameliorates this limitation and also provides more specific pathological correlates of diffusion properties than single tensor models \[[@CR76]\]. However, unlike multi-tensor models or any tractography-based analysis, our method is valuable for its clinical applicability. Region of interest analysis can be performed on scanner outputted FA maps in the absence of patient motion and are not dependent upon user-defined tracking parameters.

Conclusion {#Sec20}
==========

We found evidence of white matter underconnectivity in multiple distinct brain regions over the first 2 years of life in TSC, a single gene disorder with high penetrance of ASD. Future studies examining brain-behavior relationships in TSC+ASD are warranted to improve our understanding of the neural substrates of ASD.
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**Additional file 1: Table S1.** Clinical T1, T2, and Diffusion-weighted MR protocols 1 for the TACERN study. **Table S2.** Full longitudinal mixed effect model results for longitudinal trajectories of fractional anisotropy (FA) in each white matter ROI. **Table S3.** Full longitudinal mixed effect model results for longitudinal trajectories of mean diffusivity (MD) in each white matter ROI. Model estimates are scaled X 1000.
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